To include your compound in the COVID-19 Resource Center, submit it here.

Editas, BlueRock to combine technologies for engineered cell medicines

Gene editing company Editas and cell therapy play BlueRock are collaborating to develop engineered, allogeneic cell

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE